These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9559786)

  • 1. Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140.
    Bantia S; Ghate AA; Ananth SL; Babu YS; Air GM; Walsh GM
    Antimicrob Agents Chemother; 1998 Apr; 42(4):801-7. PubMed ID: 9559786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Passaging of an influenza A(H1N1)pdm09 virus in a difluoro sialic acid inhibitor selects for a novel, but unfit I106M neuraminidase mutant.
    McKimm-Breschkin JL; Barrett S; McKenzie-Kludas C; McAuley J; Streltsov VA; Withers SG
    Antiviral Res; 2019 Sep; 169():104542. PubMed ID: 31233807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en.
    Gubareva LV; Bethell R; Hart GJ; Murti KG; Penn CR; Webster RG
    J Virol; 1996 Mar; 70(3):1818-27. PubMed ID: 8627706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en.
    Gubareva LV; Robinson MJ; Bethell RC; Webster RG
    J Virol; 1997 May; 71(5):3385-90. PubMed ID: 9094607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors.
    McKimm-Breschkin JL; Sahasrabudhe A; Blick TJ; McDonald M; Colman PM; Hart GJ; Bethell RC; Varghese JN
    J Virol; 1998 Mar; 72(3):2456-62. PubMed ID: 9499107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations affecting the sensitivity of the influenza virus neuraminidase to 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid.
    Goto H; Bethell RC; Kawaoka Y
    Virology; 1997 Nov; 238(2):265-72. PubMed ID: 9400599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071.
    Tai CY; Escarpe PA; Sidwell RW; Williams MA; Lew W; Wu H; Kim CU; Mendel DB
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3234-41. PubMed ID: 9835519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201.
    Smee DF; Sidwell RW; Morrison AC; Bailey KW; Baum EZ; Ly L; Wagaman PC
    Antiviral Res; 2001 Dec; 52(3):251-9. PubMed ID: 11675142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en.
    McKimm-Breschkin JL; Blick TJ; Sahasrabudhe A; Tiong T; Marshall D; Hart GJ; Bethell RC; Penn CR
    Antimicrob Agents Chemother; 1996 Jan; 40(1):40-6. PubMed ID: 8787876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A release-competent influenza A virus mutant lacking the coding capacity for the neuraminidase active site.
    Gubareva LV; Nedyalkova MS; Novikov DV; Murti KG; Hoffmann E; Hayden FG
    J Gen Virol; 2002 Nov; 83(Pt 11):2683-2692. PubMed ID: 12388803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en.
    Staschke KA; Colacino JM; Baxter AJ; Air GM; Bansal A; Hornback WJ; Munroe JE; Laver WG
    Virology; 1995 Dec; 214(2):642-6. PubMed ID: 8553569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay.
    Gubareva LV; Webster RG; Hayden FG
    Antiviral Res; 2002 Jan; 53(1):47-61. PubMed ID: 11684315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.
    McSharry JJ; McDonough AC; Olson BA; Drusano GL
    Clin Diagn Lab Immunol; 2004 Jan; 11(1):21-8. PubMed ID: 14715540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accumulation of defective neuraminidase (NA) genes by influenza A viruses in the presence of NA inhibitors as a marker of reduced dependence on NA.
    Nedyalkova MS; Hayden FG; Webster RG; Gubareva LV
    J Infect Dis; 2002 Mar; 185(5):591-8. PubMed ID: 11865415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuraminidase inhibitor susceptibility and neuraminidase enzyme kinetics of human influenza A and B viruses circulating in Thailand in 2010-2015.
    Tewawong N; Marathe BM; Poovorawan Y; Vongpunsawad S; Webby RJ; Govorkova EA
    PLoS One; 2018; 13(1):e0190877. PubMed ID: 29324781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en.
    Blick TJ; Tiong T; Sahasrabudhe A; Varghese JN; Colman PM; Hart GJ; Bethell RC; McKimm-Breschkin JL
    Virology; 1995 Dec; 214(2):475-84. PubMed ID: 8553549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sialidase activity of influenza A virus in an endocytic pathway enhances viral replication.
    Suzuki T; Takahashi T; Guo CT; Hidari KI; Miyamoto D; Goto H; Kawaoka Y; Suzuki Y
    J Virol; 2005 Sep; 79(18):11705-15. PubMed ID: 16140748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.
    Molla A; Kati W; Carrick R; Steffy K; Shi Y; Montgomery D; Gusick N; Stoll VS; Stewart KD; Ng TI; Maring C; Kempf DJ; Kohlbrenner W
    J Virol; 2002 Jun; 76(11):5380-6. PubMed ID: 11991966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en.
    Blick TJ; Sahasrabudhe A; McDonald M; Owens IJ; Morley PJ; Fenton RJ; McKimm-Breschkin JL
    Virology; 1998 Jun; 246(1):95-103. PubMed ID: 9656997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host.
    Thompson CI; Barclay WS; Zambon MC
    J Antimicrob Chemother; 2004 May; 53(5):759-65. PubMed ID: 15028666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.